250 related articles for article (PubMed ID: 26672637)
1. A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency.
Moore WV; Nguyen HJ; Kletter GB; Miller BS; Rogers D; Ng D; Moore JA; Humphriss E; Cleland JL; Bright GM
J Clin Endocrinol Metab; 2016 Mar; 101(3):1091-7. PubMed ID: 26672637
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW
Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
[TBL] [Abstract][Full Text] [Related]
3. 24-month use of once-weekly GH, LB03002, in prepubertal children with GH deficiency.
Khadilkar V; Radjuk KA; Bolshova E; Khadgawat R; El Kholy M; Desai M; Peterkova V; Mericq V; Kratzsch J; Siepl EC; Martin D; Lopez P; Ji HJ; Bae YJ; Lee JH; Saenger PH
J Clin Endocrinol Metab; 2014 Jan; 99(1):126-32. PubMed ID: 24170106
[TBL] [Abstract][Full Text] [Related]
4. Three-year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD).
Péter F; Bidlingmaier M; Savoy C; Ji HJ; Saenger PH
J Clin Endocrinol Metab; 2012 Feb; 97(2):400-7. PubMed ID: 22162481
[TBL] [Abstract][Full Text] [Related]
5. A long-acting human growth hormone with delayed clearance (VRS-317): results of a double-blind, placebo-controlled, single ascending dose study in growth hormone-deficient adults.
Yuen KC; Conway GS; Popovic V; Merriam GR; Bailey T; Hamrahian AH; Biller BM; Kipnes M; Moore JA; Humphriss E; Bright GM; Cleland JL
J Clin Endocrinol Metab; 2013 Jun; 98(6):2595-603. PubMed ID: 23585663
[TBL] [Abstract][Full Text] [Related]
6. Long-Acting C-Terminal Peptide-Modified hGH (MOD-4023): Results of a Safety and Dose-Finding Study in GHD Children.
Zelinska N; Iotova V; Skorodok J; Malievsky O; Peterkova V; Samsonova L; Rosenfeld RG; Zadik Z; Jaron-Mendelson M; Koren R; Amitzi L; Raduk D; Hershkovitz O; Hart G
J Clin Endocrinol Metab; 2017 May; 102(5):1578-1587. PubMed ID: 28323965
[TBL] [Abstract][Full Text] [Related]
7. A Randomized Phase 2 Study of Long-Acting TransCon GH vs Daily GH in Childhood GH Deficiency.
Chatelain P; Malievskiy O; Radziuk K; Senatorova G; Abdou MO; Vlachopapadopoulou E; Skorodok Y; Peterkova V; Leff JA; Beckert M;
J Clin Endocrinol Metab; 2017 May; 102(5):1673-1682. PubMed ID: 28201598
[TBL] [Abstract][Full Text] [Related]
8. [Effect of recombinant human growth hormone on glucose metabolism in children with growth hormone deficiency].
Liang L; Zou CC; Li Y; Wang CL; Jiang YJ; Dong GP; Fu JF; Wang XM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):657-61. PubMed ID: 17217656
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of LB03002, a once-weekly sustained-release human GH for 12-month treatment in Korean children with GH deficiency.
Hwang JS; Lee HS; Chung WY; Han HS; Jin DK; Kim HS; Ko CW; Lee BC; Lee DY; Lee KH; Shin JH; Suh BK; Yoo HW; Ji HJ; Lee JH; Bae YJ; Kim DH; Yang SW
Eur J Endocrinol; 2013 Aug; 169(2):179-85. PubMed ID: 23682096
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a new ready-to-use recombinant human growth hormone solution.
Romer T; Peter F; Saenger P; Starzyk J; Koehler B; Korman E; Walczak M; Wasik R; Ginalska-Malinowska M; Solyom E; Berghout A
J Endocrinol Invest; 2007; 30(7):578-89. PubMed ID: 17848841
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind study to assess the efficacy and safety of valtropin, a biosimilar growth hormone, in children with growth hormone deficiency.
Peterkova V; Arslanoglu I; Bolshova-Zubkovskaya E; Romer T; Zdravkovic D; Kratzsch J; Ji HJ; Savoy C; Saenger P
Horm Res; 2007; 68(6):288-93. PubMed ID: 17627092
[TBL] [Abstract][Full Text] [Related]
12. Long-acting FC-fusion rhGH (GX-H9) shows potential for up to twice-monthly administration in GH-deficient adults.
Ku CR; Brue T; Schilbach K; Ignatenko S; Magony S; Chung YS; Kim BJ; Hur KY; Kang HC; Kim JH; Kim MS; Kowalska A; Bolanowski M; Ruchala M; Damjanovic S; Payer J; Choi YJ; Heo SJ; Kim TK; Heo M; Lee J; Lee EJ
Eur J Endocrinol; 2018 Sep; 179(3):169-179. PubMed ID: 29973375
[TBL] [Abstract][Full Text] [Related]
13. A multicenter study of the efficacy and safety of sustained release GH in the treatment of naive pediatric patients with GH deficiency.
Reiter EO; Attie KM; Moshang T; Silverman BL; Kemp SF; Neuwirth RB; Ford KM; Saenger P;
J Clin Endocrinol Metab; 2001 Oct; 86(10):4700-6. PubMed ID: 11600528
[TBL] [Abstract][Full Text] [Related]
14. Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial.
Midyett LK; Rogol AD; Van Meter QL; Frane J; Bright GM;
J Clin Endocrinol Metab; 2010 Feb; 95(2):611-9. PubMed ID: 19880790
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
[TBL] [Abstract][Full Text] [Related]
16. Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope in the treatment of growth hormone deficient children: results of a phase III study.
Romer T; Saenger P; Peter F; Walczak M; Le Bouc Y; Khan-Boluki J; Berghout A
Horm Res; 2009; 72(6):359-69. PubMed ID: 19844125
[TBL] [Abstract][Full Text] [Related]
17. Reduced Effectiveness and Comparable Safety in Biweekly
Sun C; Lu B; Liu Y; Zhang Y; Wei H; Hu X; Hu P; Zhao Q; Liu Y; Ye K; Wang K; Gu Z; Liu Z; Ye J; Zhang H; Zhu H; Jiang Z; Liu Y; Wan N; Yan C; Yin J; Ying L; Huang F; Yin Q; Xi L; Luo F; Cheng R
Front Endocrinol (Lausanne); 2021; 12():779365. PubMed ID: 34899612
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human growth hormone plus recombinant human insulin-like growth factor-1 coadministration therapy in short children with low insulin-like growth factor-1 and growth hormone sufficiency: results from a randomized, multicenter, open-label, parallel-group, active treatment-controlled trial.
Backeljauw PF; Miller BS; Dutailly P; Houchard A; Lawson E; Hale DE; Reiner B; Sperling MA;
Horm Res Paediatr; 2015; 83(4):268-79. PubMed ID: 25765099
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient children.
Kemp SF; Fielder PJ; Attie KM; Blethen SL; Reiter EO; Ford KM; Marian M; Dao LN; Lee HJ; Saenger P
J Clin Endocrinol Metab; 2004 Jul; 89(7):3234-40. PubMed ID: 15240597
[TBL] [Abstract][Full Text] [Related]
20. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study.
Cohen P; Rogol AD; Howard CP; Bright GM; Kappelgaard AM; Rosenfeld RG;
J Clin Endocrinol Metab; 2007 Jul; 92(7):2480-6. PubMed ID: 17356043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
